CAR T-Cell Co-Stimulation via NF-κB Activation for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adoptive T-cell immunotherapy approaches for cancer are limited by the need for HLA matching and the inability to target tumor cells with down-regulated HLA expression or proteasomal antigen processing, and there is a need for improved activation mechanisms to enhance T-cell efficacy.
Innovation Solution
Development of immune cells expressing non-naturally occurring immune receptors, such as chimeric antigen receptors (CARs) and agents that selectively activate the NF-κB signaling pathway, allowing for broad antigen recognition and enhanced T-cell activation and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T-cell receptor (TCR) is used to recognize tumor antigens, then specific immune response is activated, but HLA matching is required and tumor cells with down-regulated HLA expression cannot be targeted
Solution Approach 1:
The patent introduces chimeric antigen receptors (CARs) as intermediary structures that mediate between T-cells and tumor antigens. CARs contain antigen-binding domains that directly recognize tumor surface antigens without requiring HLA presentation, thereby bypassing the HLA matching requirement and enabling targeting of HLA-downregulated tumor cells while maintaining T-cell activation capability
2Adaptability or versatility
If conventional CAR design is used to bypass HLA requirements, then broad antigen recognition is achieved, but T-cell activation and persistence are insufficient
Solution Approach 1:
The patent creates composite CAR structures that integrate multiple functional domains: antigen-binding domains (for broad recognition), costimulatory domains (for enhanced activation), and signaling domains (for persistent activation). The composite design combines NF-κB pathway activation with traditional costimulatory signals, producing synergistic effects that improve T-cell activation, proliferation, and persistence beyond what single-domain CARs achieve
3Productivity
If T-cell proliferation is enhanced to improve treatment efficacy, then tumor killing capacity increases, but T-cell exhaustion and loss of function occur faster
Solution Approach 1:
The patent implements dynamic control of T-cell activation through inducible CAR expression systems and regulated NF-κB pathway activation. The system can adjust activation levels in response to tumor burden and treatment progression, enabling sustained T-cell function by preventing exhaustion while maintaining adequate proliferation and tumor killing capacity throughout the treatment course
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables T-cells to target a wide range of tumor antigens, including those with reduced HLA expression, and enhances T-cell longevity, proliferation, and cytokine production, improving cancer treatment efficacy.
Implementation Method 1
agents that selectively activate the NF-κB signaling pathway, allowing for broad antigen recognition and enhanced T-cell activation and proliferation
Implementation Method 2
CARs engage molecules that do not require peptide processing or HLA expression to be recognized. CARs therefore recognize antigen on any HLA background
Data Source
AI summary
The disclosure provides compositions and method that promote adoptive cellular therapy. The disclosure provides polynucleotides, vectors, systems and cells comprising chimeric antigen receptors (CARs), synthetic immune receptors (SIRs), and the like in combination the specific activators of NFkB activity, thus improving cellular proliferation, expression and reduced apoptosis, which improves cell persistence in adoptive cell therapy.